ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACAD ACADIA Pharmaceuticals

Pre-Mkt 10-08 08:34:11 EDT

19.65

-0.09

-0.46%

盘前19.80

+0.15+0.75%

08:04 EDT

High19.80	Low19.46	Vol1.78M
Open19.60	D1 Closing19.74	Amplitude1.73%
Mkt Cap3.39B	Tradable Cap2.53B	Total Shares172.31M
T/O35.02M	T/O Rate1.39%	Tradable Shares128.72M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACAD","market":"US","secType":"STK","nameCN":"ACADIA Pharmaceuticals","latestPrice":19.65,"timestamp":1791403200000,"preClose":19.74,"halted":0,"volume":1784747,"hourTrading":{"tag":"盘前","latestPrice":19.7965,"preClose":19.65,"latestTime":"08:04 EDT","volume":3085,"amount":61067.004275,"timestamp":1791461076527,"change":0.1465,"changeRate":0.007455,"amplitude":0},"delay":0,"changeRate":-0.004559270516717318,"floatShares":128722546,"shares":172305518,"eps":2.195511,"marketStatus":"Pre-Mkt","change":-0.09,"latestTime":"10-08 08:34:11 EDT","open":19.6,"high":19.7968,"low":19.455,"amount":35015988.331007004,"amplitude":0.017315,"askPrice":19.75,"askSize":22,"bidPrice":19.46,"bidSize":22,"shortable":3,"etf":0,"ttmEps":2.195511,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791466200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1085630400000,"exchange":"NASDAQ","adjPreClose":19.65,"preHourTrading":{"tag":"盘前","latestPrice":19.7965,"preClose":19.65,"latestTime":"08:04 EDT","volume":3085,"amount":61067.004275,"timestamp":1791461076527,"change":0.1465,"changeRate":0.007455,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":19.7,"preClose":19.65,"latestTime":"19:30 EDT","volume":91814,"amount":1804164.17,"timestamp":1791415801796,"change":0.05,"changeRate":0.002545,"amplitude":0.002545},"volumeRatio":0.6735426056649335,"impliedVol":0.5435,"impliedVolPercentile":0.804},"requestUrl":"/m/hq/s/ACAD/tweets","defaultTab":"tweets","newsList":[{"id":"2673207994","title":"RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2673207994","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673207994?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:03","pubTimestamp":1791457418,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $31.95, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673073702","title":"Acadia Pharmaceuticals Inc. : RBC Cuts Target Price to $36 from $37","url":"https://stock-news.laohu8.com/highlight/detail?id=2673073702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673073702?lang=en_us&edition=fundamental","pubTime":"2026-10-08 18:02","pubTimestamp":1791453723,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nFWN45U0WQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ACAD","LU2065169927.USD","LU2065170008.USD","LU2065171402.SGD","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673034134","title":"Acadia Pharmaceuticals (ACAD) After Patent And RADIANT Updates Is The Undervalued View Too Simple","url":"https://stock-news.laohu8.com/highlight/detail?id=2673034134","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673034134?lang=en_us&edition=fundamental","pubTime":"2026-10-06 15:14","pubTimestamp":1791270858,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals (ACAD) just picked up two important pipeline milestones. Fresh US patent protection for Rett therapy trofinetide and Phase 2 RADIANT data for remlifanserin are now in focus for anyone tracking the stock.\nDespite this twin pipeline update, Acadia Pharmaceuticals’ share price has fallen about 28% over the past month and about 23% year to date, while the 1-year total shareholder return is down roughly 7%. This suggests that recent news is being weighed against longer term...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/acadia-pharmaceuticals-acad-after-patent-and-radiant-updates","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-acad/acadia-pharmaceuticals/news/acadia-pharmaceuticals-acad-after-patent-and-radiant-updates","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065169927.USD","ACAD","LU2065171311.SGD","LU2065170008.USD","LU2065171402.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673086090","title":"Acadia looks to have settled case with Zydus, says RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2673086090","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673086090?lang=en_us&edition=fundamental","pubTime":"2026-10-06 01:35","pubTimestamp":1791221721,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams says the firm’s checks found that Acadia Pharmaceuticals (ACAD) and generic drugmaker Zydus filed a joint stipul...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acadia-looks-to-have-settled-case-with-zydus-says-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acadia-looks-to-have-settled-case-with-zydus-says-rbc-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065169927.USD","BK4207","BK4080","LU0128525929.USD","LU0310800379.SGD","GSIB","LU2065171402.SGD","LU0708994859.HKD","LU2065170008.USD","AKR","BK4231","LU1267930573.SGD","ACAD","LU2065171311.SGD","BK4139","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671301268","title":"Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2671301268","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671301268?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:17","pubTimestamp":1790630276,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals  said late Monday the US Patent and Trademark Office issued a notice of allowance for a patent application covering weight-banded dosing of trofinetide for the treatment of Rett syndrome.The company said the patent, if issued, is expected to provide US protection for trofinetide through March 28, 2041, including six months of pediatric exclusivity, extending protection by nearly five years.Trofinetide is marketed in the US as \"Daybue\" and \"Daybue Stix\" for the treatment of Rett syndrome in adults and children age 2 and older. The drug is also covered by a method-of-use patent that expires in July 2036, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["USRD","BK4139","AKR","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","ACAD","BK4080","BK4231","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671683972","title":"Helix BioPharma Names Karen Krumeich Board Chair, Adds Three Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2671683972","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671683972?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:15","pubTimestamp":1790630131,"startTime":"0","endTime":"0","summary":"Helix BioPharma names Karen Krumeich board chair, adds three directorsHelix BioPharma appointed Karen Krumeich, Jamieson Bondarenko, Charmaine Lykins, Dirk Brockstedt to its board, effective Sept. 28,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL9JqR7K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109981661.USD","BK4139","IE00BWDBJ516.SGD","LU0114720955.EUR","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU1868836591.USD","IE00BSNM7G36.USD","LU2125154778.USD","IE00BJJMRZ35.SGD","LU0306806265.USD","LU1868836914.USD","BK4581","LU2596442595.SGD","LU1989771016.USD","LU2065169927.USD","IE00B3T34201.USD","BK5011","SG9999001176.SGD","LU2133065610.SGD","LU1487256676.USD","LU0058720904.USD","LU1400636574.HKD","LU1236620750.USD","LU2065171311.SGD","BK4588","LU0161305163.EUR","LU1400636657.SGD","LU1309081286.SGD","IE0002141913.USD","LU2125154935.USD","BK4007","FTXH","LU1430594728.SGD","LU0306807586.USD","LU1074936037.SGD","LU0575583348.USD","LU2065171402.SGD","LU0971552673.USD","IHE","IE00B2B36J28.USD","BMY","LU0985481810.HKD","IE0034235071.USD","LU0203345920.USD","LU1032466523.USD","GSK.UK","ACAD","LU1645745479.HKD","LU2646069778.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671257465","title":"Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, Extending U.S. Patent Protections to March 2041","url":"https://stock-news.laohu8.com/highlight/detail?id=2671257465","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671257465?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625936,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nFWN45K0GB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171402.SGD","ACAD","LU2065171311.SGD","LU2065170008.USD","BK4139","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670607429","title":"Axsome's Auvelity Continues Positive Launch Trend, Mizuho Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670607429","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670607429?lang=en_us&edition=fundamental","pubTime":"2026-09-26 01:42","pubTimestamp":1790358164,"startTime":"0","endTime":"0","summary":"Axsome Therapeutics  may benefit from continued momentum for its depression and Alzheimer's agitation treatment Auvelity, with prescription data showing solid weekly growth, Mizuho said Friday in a report.Data from Bloomberg Symphony and IQVIA indicated double-digit percentage increases in total and new prescriptions, suggesting Auvelity's launch in Alzheimer's agitation is off to an encouraging start, the report said.The positive trends emerge as competitor Acadia Pharmaceuticals  reported weaker phase 2 results in Alzheimer's-related psychosis, which may help Axsome's positioning in the Alzheimer's and depression treatment markets, Mizuho said.Mizuho maintained its outperform rating on Axsome with a $316 price target.Price: 196.49, Change: +0.46, Percent Change: +0.23","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ACAD","LU2324357040.USD","BK4585","LU2065171311.SGD","PTH","LU2065169927.USD","AXSM","BK4007","LU2065171402.SGD","BK4139","BK4505","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670542610","title":"Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670542610","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670542610?lang=en_us&edition=fundamental","pubTime":"2026-09-26 00:34","pubTimestamp":1790354048,"startTime":"0","endTime":"0","summary":"Acadia Pharmaceuticals'  favorable risk-reward remains intact despite remlifanserin narrowly missing statistical significance in a phase 2 trial in Alzheimer's disease psychosis, with the commercial base business supporting valuation, Deutsche Bank said in a Friday note.The 60 milligram dose narrowly missed statistical significance, but Deutsche Bank said the data showed a dose response, separation from placebo beginning at Week 2 and widening through Week 6, and a clean safety profile.The bank said remlifanserin has a pimavanserin-like profile that could be attractive commercially, supported by long-dated intellectual property.Deutsche Bank also cited improving commercial prospects for Nuplazid and Daybue.The investment bank reduced its probability of success for remlifanserin in Alzheimer's disease psychosis and Lewy body dementia psychosis.Deutsche Bank maintained its Buy rating and lowered its price target to $31 from $38.Shares of Acadia were 5.7% lower in Friday afternoon trading","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DB","BK4552","BK4080","BK4588","LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD","AKR","BK4566","BK4231","BK4585","ACAD","LU2065171311.SGD","BK4139","BK4118"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442447","title":"Deutsche Bank Lowers Price Target on ACADIA Pharmaceuticals to $31 From $38, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442447?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:30","pubTimestamp":1790335828,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals (ACAD) has an average rating of overweight and mean price target of $32.37, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DB","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670427544","title":"BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670427544","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670427544?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:25","pubTimestamp":1790335516,"startTime":"0","endTime":"0","summary":"BMO Capital analyst Malcolm Hoffman maintained a Buy rating on ACADIA Pharmaceuticals today and set a price target of $34.00. According to TipRanks...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-its-buy-rating-for-acadia-pharmaceuticals-acad-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bmo-capital-sticks-to-its-buy-rating-for-acadia-pharmaceuticals-acad-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670442302","title":"Acadia Pharmaceuticals Inc. : Deutsche Bank Cuts Target Price to $31 from $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2670442302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670442302?lang=en_us&edition=fundamental","pubTime":"2026-09-25 19:07","pubTimestamp":1790334428,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nAQN2MKSQH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACAD","LU2065170008.USD","LU2065171402.SGD","LU2065171311.SGD","BK4139","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670412443","title":"US Research Roundup-Chevron, Exxon Mobil, GoDaddy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412443?lang=en_us&edition=fundamental","pubTime":"2026-09-25 14:58","pubTimestamp":1790319529,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddySept 25 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Chevron, Exxon Mobi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nL4N45H0CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKAM","XLP","AEE","RSPC","SO","AXGN","GEN","CF","ACAD","PYPL","CMCSA","COST","FFBC","DRI","FUL","GRAL","NTRA","CRK","KMX","UGE","CPT","BNY","CRL","FSTA","GPOR","TRUN","MMM","DMRA","KNF","META","STZ","XOM","INFQ","ALM","GDDY","CVX","OKTA","ANDG","HELX","OILT","P","CGEM","UPW","LMRI","OBK","CNK","EMR","CDNL","GXPE","TRUC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670341093","title":"Acadia Pharmaceuticals Inc. : Oppenheimer Cuts Target Price to $23 from $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2670341093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670341093?lang=en_us&edition=fundamental","pubTime":"2026-09-25 13:10","pubTimestamp":1790313048,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nFWN45H06O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065170008.USD","BK4139","LU2065171402.SGD","LU2065169927.USD","ACAD","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669945074","title":"US Stocks on the MOVE-Charles River, Oracle, TD Synnex","url":"https://stock-news.laohu8.com/highlight/detail?id=2669945074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669945074?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:44","pubTimestamp":1790264673,"startTime":"0","endTime":"0","summary":"BUZZ-US STOCKS ON THE MOVE-Charles River, Oracle, TD SynnexSeptember 24 (Reuters)-Wall Street's main indexes dropped on Thursday as uncertainty over prospects for a resolution to the Middle East confl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL6N45G10O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XOM","CVX","GRML","VSNT","XXII","GETY","WHLR","IHE","SNX","TLT","DAVA","AGNG","DK","ROL","VOYG","IXJ","ARES","ATYR","CG","MGM","KYTX","PIPR","OWL","OXY","DRI","PWR","IEF","ERX","AU","ORCL","RSKD","LU","SFIX","SRZN","CTEC","CORD","APA","PMAX","ACAD","TWST","FSLR","CRWV","LLY","P","NEM","DBX","CRL","VKTX","VLO","IXC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669638491","title":"Acadia Pharmaceuticals Down over 8%, on Pace for Largest Percent Decrease Since September 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2669638491","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669638491?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:02","pubTimestamp":1790262120,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals Inc.  is currently at $23.24, down $2.20 or 8.63%--Would be lowest close since June 23, 2026, when it closed at $22.60--On pace for largest percent decrease since Sept. 24, 2025, when it fell 9.92%--Currently down five of the past six days--Currently down two consecutive days; down 12.02% over this period--Worst two day stretch since the two days ending Sept. 24, 2025, when it fell 13.33%--Down 19.63% month-to-date; on pace for worst month since March 2024, when it fell 20.44%--Down 13.01% year-to-date--Down 59.24% from its all-time closing high of $57.00 on July 7, 2020--Up 9.55% from 52 weeks ago , when it closed at $21.21--Down 23.99% from its 52-week closing high of $30.57 on Aug. 25, 2026--Up 15.83% from its 52-week closing low of $20.06 on Oct. 13, 2025--Traded as low as $21.97; lowest intraday level since June 22, 2026, when it hit $21.59--Down 13.61% at today's intraday low; largest intraday percent decrease since Sept. 24, 2025, when it fell as much as 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKR","LU2065171311.SGD","LU2065169927.USD","ACAD","BK4231","BK4080","BK4139","LU2065171402.SGD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669493651","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669493651","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669493651?lang=en_us&edition=fundamental","pubTime":"2026-09-24 21:02","pubTimestamp":1790254979,"startTime":"0","endTime":"0","summary":"Healthcare stocks were flat to higher pre-bell Thursday, with the iShares Biotechnology ETF  inactive and the State Street Health Care Select Sector SPDR ETF  up 0.3%.ACADIA Pharmaceuticals  shares were down more than 4% in premarket activity after the company reported that its phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis narrowly missed its primary endpoint.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2065169927.USD","BK4588","LU2065170008.USD","LU2065171311.SGD","XLV","LU0128526141.USD","IBB","BK4137","LABU","ACAD","HCSG","BK4581","LU2065171402.SGD","XBI","BK4585","LU0029874061.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669446047","title":"U.S. Stocks on the MOVE-Everpure, Dropbox, Darden Restaurants","url":"https://stock-news.laohu8.com/highlight/detail?id=2669446047","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669446047?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:12","pubTimestamp":1790251979,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Everpure, Dropbox, Darden RestaurantsSeptember 24 (Reuters)-Wall Street futures dropped on Thursday as the Middle East conflict remained far from a resolution, while inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL6N45G0Q9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARKG","BK4209","LU2265009873.SGD","OZEM","BK4534","PUL","BK4585","BK4139","TLTI","HWAY","LU1642822529.SGD","TLTX","BK4532","LU0957808578.USD","P","TSYW","LU0323239441.USD","POW","IEF","LU2106854487.HKD","BK4567","TLH","LU2065171402.SGD","LU1093756325.SGD","LU1093756168.USD","LU1804176565.USD","BWX","LU0323240290.USD","LU1261432733.SGD","TBJL","BBLB","LU2023250843.SGD","LU2065171311.SGD","LU2023250504.SGD","LU1974910355.USD","BK4150","BK4551","LU2087625088.SGD","ACAD","SGOV","BK4094","LU2237438978.USD","BK4561","MGM","BK4528","SG9999001440.SGD","DRI","LU1815336760.USD","ISHG","FLGV","BK4129","TWST","ODDZ","ZAP","GNOM","BK4588","TLTW","BK4598","KYTX","BBIB","IEI","SHY","POWR","LU2065169927.USD","PWR","BK4170","BBSB","LU0353189680.USD","TLT","GRML","LU1571399168.USD","BK4599","LU0154245673.USD","GRID","TFJL","BK4122","LU2065170008.USD","VKTX","DBX","SFIX","BK4581","BWZ","BK4504","IGOV","LU0353189763.USD","THNR","LU0444971666.USD","LU2394011477.USD","WDNA","JOUL","IDNA","BK4023","LU0154245756.USD","SHV","LU1917777945.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669467211","title":"ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2669467211","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669467211?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:47","pubTimestamp":1790250440,"startTime":"0","endTime":"0","summary":"ACADIA Pharmaceuticals'  shares dropped 10% pre-bell after it reported that its phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis narrowly missed its primary endpoint.The primary endpoint was the change from baseline in the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales at week six.The study showed the 60 mg dose achieved nominal statistical significance on the key secondary Clinical Global Impression-Severity for Alzheimer's Disease Psychosis endpoint, while the 30 mg dose showed minimal improvement across endpoints versus placebo.Across both doses, the rates of adverse events, serious adverse events, and discontinuations due to adverse events were similar to placebo.The company said it plans to continue enrolling its two ongoing phase 3 studies evaluating remlifanserin in Alzheimer's disease psychosis, while amending the phase 3 program to remove the 30 mg dosage arm.It also said remlifanserin is currently being investigate","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ACAD","LU2065170008.USD","LU2065169927.USD","LU2065171311.SGD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669673924","title":"Acadia Falls After Alzheimer's-Related Drug Narrowly Misses Goal in Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669673924","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669673924?lang=en_us&edition=fundamental","pubTime":"2026-09-24 19:26","pubTimestamp":1790249174,"startTime":"0","endTime":"0","summary":"BUZZ-Acadia falls after Alzheimer's-related drug narrowly misses goal in study** Acadia PharmaceuticalsACAD.Oshares fall 15.6% to $21.45 premarket** Cosaysits experimental drug remlifanserin narrowly ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nL4N45G0WF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065169927.USD","LU2065171311.SGD","BK4139","LU2065170008.USD","ACAD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acadia.com","stockEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.2987},{"period":"3month","weight":-0.256},{"period":"6month","weight":-0.0961},{"period":"1year","weight":-0.0877},{"period":"ytd","weight":-0.2643}],"compareEarnings":[{"period":"1week","weight":0.0191},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.0339},{"period":"6month","weight":0.1439},{"period":"1year","weight":0.1616},{"period":"ytd","weight":0.1398}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.058102},{"month":2,"riseRate":0.636364,"avgChangeRate":0.023325},{"month":3,"riseRate":0.409091,"avgChangeRate":0.049753},{"month":4,"riseRate":0.454545,"avgChangeRate":0.00093},{"month":5,"riseRate":0.545455,"avgChangeRate":0.056897},{"month":6,"riseRate":0.521739,"avgChangeRate":-0.007217},{"month":7,"riseRate":0.608696,"avgChangeRate":0.051329},{"month":8,"riseRate":0.565217,"avgChangeRate":0.019184},{"month":9,"riseRate":0.478261,"avgChangeRate":0.009767},{"month":10,"riseRate":0.434783,"avgChangeRate":-0.024847},{"month":11,"riseRate":0.454545,"avgChangeRate":0.031974},{"month":12,"riseRate":0.545455,"avgChangeRate":0.059204}],"exchange":"NASDAQ","name":"ACADIA Pharmaceuticals","nameEN":"ACADIA Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ACADIA Pharmaceuticals,ACAD,ACADIA Pharmaceuticals股票,ACADIA Pharmaceuticals股票老虎,ACADIA Pharmaceuticals股票老虎国际,ACADIA Pharmaceuticals行情,ACADIA Pharmaceuticals股票行情,ACADIA Pharmaceuticals股价,ACADIA Pharmaceuticals股市,ACADIA Pharmaceuticals股票价格,ACADIA Pharmaceuticals股票交易,ACADIA Pharmaceuticals股票购买,ACADIA Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ACADIA Pharmaceuticals(ACAD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ACADIA Pharmaceuticals(ACAD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}